Daniel Halperin

Department of Hematology and Medical Oncology
Associate Professor

daniel.mark.halperin@emory.edu

Overview

Daniel M. Halperin, MD, is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. As vice chair of clinical affairs, he works with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department.

A board-certified medical oncologist, Dr. Halperin specializes in the treatment of neuroendocrine tumors (NETs). Dr. Halperin is a physician on the gastrointestinal oncology team at Winship Cancer Institute of Emory University.

Dr. Halperin received his medical degree from Weill Cornell Medical College in New York City, New York. He completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.

Academic Appointment

Associate Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from Weill Cornell Medicine

Research

Publications

Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.
Future Oncol Volume: 21 Page(s): 1357 - 1363
05/01/2025 Authors: Grewal US; Gbolahan OB; Takalkar AM; Halperin DM
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.
Clin Cancer Res Volume: 31 Page(s): 1657 - 1666
05/01/2025 Authors: Morris VK; Liu S; Lin K; Zhu H; Prasad S; Mahvash A; Bhosale P; Sun B; Parra ER; Wistuba I
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET).
J Neuroendocrinol Volume: 37 Page(s): e13496
04/01/2025 Authors: Morse MA; Crosby EJ; Halperin DM; Uronis HE; Hsu SD; Hurwitz HI; Rushing C; Bolch EK; Warren DA; Moyer AN
Classification of Gastric Neuroendocrine Tumors and Associations With Survival.
Volume: 131 Page(s): 204 - 211
02/01/2025 Authors: Song Y; Chen E; Chiang Y-J; Yao JC; Halperin DM; Chatterjee D; Badgwell BD
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
Clin Cancer Res Volume: 30 Page(s): 5559 - 5567
12/16/2024 Authors: Meng QH; Halfdanarson TR; Bornhorst JA; Jann H; Shaheen S; Shi RZ; Schwabe A; Stade K; Halperin DM
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.
NPJ Precis Oncol Volume: 8 Page(s): 268
11/31/2024 Authors: Serrano AG; Rocha P; Freitas Lima C; Stewart A; Zhang B; Diao L; Fujimoto J; Cardnell RJ; Lu W; Khan K
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.
Curr Oncol Rep Volume: 26 Page(s): 1530 - 1542
11/01/2024 Authors: Fields BC; Ayabe RI; Seo YD; Maxwell JE; Halperin DM
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
JAMA Oncol Volume: 10 Page(s): 1519 - 1529
11/01/2024 Authors: Yousef M; Yousef A; Chowdhury S; Fanaeian MM; Knafl M; Peterson J; Zeineddine M; Alfaro K; Zeineddine F; Goldstein D
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus highdose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet Volume: 403 Page(s): 2807 - 2817
06/29/2024 Authors: Singh S; Halperin D; Myrehaug S; Herrmann K; Pavel M; Kunz PL; Chasen B; Tafuto S; Lastoria S; Capdevila J
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma.
Cancer Res Commun Volume: 4 Page(s): 1363 - 1368
05/29/2024 Authors: Hornstein NJ; Zeineddine MA; Gunes BB; Pellatt AJ; Knafl M; Zhu H; Willett AF; Yousef A; Liu S; Sun R
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Trials Volume: 25 Page(s): 297
05/31/2024 Authors: Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellstrm L; Liedman H; Svedberg A
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
Endocr Relat Cancer Volume: 31
04/01/2024 Authors: Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study.
Oral Oncol Volume: 151 Page(s): 106747
04/01/2024 Authors: de Sousa LG; Liu S; Bhosale P; Altan M; Darbonne W; Schulze K; Dervin S; Yun C; Mahvash A; Verma A
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide.
J Med Chem Volume: 67 Page(s): 2425 - 2437
02/22/2024 Authors: AghaAmiri S; Ghosh SC; Hernandez Vargas S; Halperin DM; Azhdarinia A
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Trials Volume: 25 Page(s): 58
01/16/2024 Authors: Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellstrm L; Liedman H; Svedberg A
Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.
J Clin Endocrinol Metab Volume: 108 Page(s): 3260 - 3271
11/17/2023 Authors: Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Wu R; Dennison JB; Peterson CB; Zhao H; Do K-A
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
J Natl Cancer Inst Volume: 115 Page(s): 1001 - 1010
09/07/2023 Authors: Singh S; Hope TA; Bergsland EB; Bodei L; Bushnell DL; Chan JA; Chasen BR; Chauhan A; Das S; Dasari A
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Cancer Immunol Res Volume: 11 Page(s): 925 - 945
07/05/2023 Authors: Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F
Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
Abdom Radiol (NY) Volume: 47 Page(s): 3962 - 3970
12/01/2022 Authors: Galgano SJ; Morani AC; Gopireddy DR; Sharbidre K; Bates DDB; Goenka AH; Arif-Tiwari H; Itani M; Iravani A; Javadi S
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
Mol Pharm Volume: 19 Page(s): 4241 - 4253
11/07/2022 Authors: Hernandez Vargas S; AghaAmiri S; Ghosh SC; Luciano MP; Borbon LC; Ear PH; Howe JR; Bailey-Lundberg JM; Simonek GD; Halperin DM
New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Abdom Radiol (NY) Volume: 47 Page(s): 3078 - 3100
09/01/2022 Authors: Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
Endocr Relat Cancer Volume: 29 Page(s): 533 - 544
09/01/2022 Authors: Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED
Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome.
Surgery Volume: 172 Page(s): 559 - 566
08/01/2022 Authors: Landry JP; Clemente-Gutierrez U; Pieterman CRC; Chiang Y-J; Waguespack SG; Jimenez C; Habra MA; Halperin DM; Fisher SB; Graham PH
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
JAMA Oncol Volume: 8 Page(s): 904 - 909
06/01/2022 Authors: Halperin DM; Liu S; Dasari A; Fogelman D; Bhosale P; Mahvash A; Estrella JS; Rubin L; Morani AC; Knafl M
Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.
Ann Surg Oncol Volume: 29 Page(s): 3072 - 3084
05/01/2022 Authors: Maxwell JE; Naraev B; Halperin DM; Choti MA; Halfdanarson TR
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Neuroendocrinology Volume: 112 Page(s): 34 - 42
01/01/2022 Authors: Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors.
J Surg Res Volume: 268 Page(s): 419 - 431
12/01/2021 Authors: Fujii Y; Tzeng C-W; Chiang Y-J; Halperin DM; Dasari A; Kim MP; Katz MHG; Lee JE; Ikoma N
A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
J Clin Endocrinol Metab Volume: 106 Page(s): e4969 - e4980
11/19/2021 Authors: Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Cancer Discov Volume: 11 Page(s): 2738 - 2747
11/01/2021 Authors: Raghav K; Liu S; Overman MJ; Willett AF; Knafl M; Fu S-C; Malpica A; Prasad S; Royal RE; Scally CP
A SystematicReview of Economic and Quality-of-Life Research in Carcinoid Syndrome.
Pharmacoeconomics Volume: 39 Page(s): 1271 - 1297
11/01/2021 Authors: Pan I-W; Halperin DM; Kim B; Yao JC; Shih Y-CT
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020.
JAMA Netw Open Volume: 4 Page(s): e2131744
10/01/2021 Authors: Das S; Du L; Lee CL; Arhin ND; Chan JA; Kohn EC; Halperin DM; Berlin J; LaFerriere H; Singh S
Operationalizing Virtual Trials in Oncology-From Aspiration to Action.
JCO Clin Cancer Inform Volume: 5 Page(s): 953 - 957
08/01/2021 Authors: Kadakia KT; Halperin DM; Offodile AC
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw Volume: 19 Page(s): 839 - 868
07/28/2021 Authors: Shah MH; Goldner WS; Benson AB; Bergsland E; Blaszkowsky LS; Brock P; Chan J; Das S; Dickson PV; Fanta P
Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index.
Neuroendocrinology Volume: 111 Page(s): 850 - 862
01/01/2021 Authors: Shaunfield S; Webster KA; Kaiser K; Greene GJ; Yount SE; Lacson L; Benson AB; Halperin DM; Yao JC; Singh S
Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
Endocr Relat Cancer
01/01/2021 Authors: Yao JC; Strosberg J; Fazio N; Pavel ME; Bergsland E; Ruszniewski P; Halperin DM; Li D; Tafuto S; Raj N
Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors.
J Biomed Opt Volume: 25
12/01/2020 Authors: Hernandez Vargas S; Lin C; Voss J; Ghosh SC; Halperin DM; AghaAmiri S; Cao HST; Ikoma N; Uselmann AJ; Azhdarinia A
Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea.
Expert Rev Pharmacoecon Outcomes Res Volume: 20 Page(s): 507 - 511
10/01/2020 Authors: Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors.
Pancreas Volume: 49 Page(s): 1123 - 1130
10/01/2020 Authors: Eads JR; Reidy-Lagunes D; Soares HP; Chan JA; Anthony LB; Halfdanarson TR; Naraev BG; Wolin EM; Halperin DM; Li D
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy.
Clin Colorectal Cancer Volume: 19 Page(s): e117 - e123
09/01/2020 Authors: Tang T; Abu-Sbeih H; Ma W; Lu Y; Luo W; Foo WC; Richards DM; Halperin DM; Ge PS; Wang Y
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
Pancreas Volume: 49 Page(s): 863 - 881
08/01/2020 Authors: Halfdanarson TR; Strosberg JR; Tang L; Bellizzi AM; Bergsland EK; O'Dorisio TM; Halperin DM; Fishbein L; Eads J; Hope TA
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives.
Endocr Relat Cancer Volume: 27 Page(s): T9 - T25
08/01/2020 Authors: Pieterman CRC; Sadowski SM; Maxwell JE; Katz MHG; Lines KE; Heaphy CM; Tirosh A; Blau JE; Perrier ND; Lewis MA
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
Pancreas Volume: 49 Page(s): 723 - 728
07/01/2020 Authors: Bergsland EK; Halperin DM; Dillon JS; Dasari NA; Kunz PL; Soares HP; Pryma D; Bodei L; Hope T; Soulen MC
History of the multiple endocrine neoplasia workshops and overview of MEN2019.
Endocr Relat Cancer
06/01/2020 Authors: Grubbs EG; Halperin DM; Waguespack SG; Gagel RF
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
Br J Cancer Volume: 122 Page(s): 1309 - 1314
04/01/2020 Authors: Vijayvergia N; Dasari A; Deng M; Litwin S; Al-Toubah T; Alpaugh RK; Dotan E; Hall MJ; Ross NM; Runyen MM
Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy.
J Cancer Volume: 11 Page(s): 3144 - 3150
01/01/2020 Authors: Abu-Sbeih H; Mallepally N; Goldstein R; Chen E; Tang T; Dike UK; Al-Asadi M; Westin S; Halperin D; Wang Y
Direct costs of carcinoid syndrome diarrhea among adults in the United States.
World J Gastroenterol Volume: 25 Page(s): 6857 - 6865
12/21/2019 Authors: Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors.
Ann Oncol Volume: 30 Page(s): 1847
11/01/2019 Authors: Shen C; Dasari A; Chu Y; Halperin DM; Zhou S; Xu Y; Shih YT; Yao JC
Management of Diarrhea in Patients With Carcinoid Syndrome.
Pancreas Volume: 48 Page(s): 961 - 972
09/01/2019 Authors: Naraev BG; Halland M; Halperin DM; Purvis AJ; ODorisio TM; Halfdanarson TR
The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment.
Oncol Lett Volume: 17 Page(s): 4126 - 4132
05/01/2019 Authors: Balanescu DV; Donisan T; Lopez-Mattei J; Hassan S; Kim P; Dasari A; Halperin D; Yao J; Kar B; Gregoric I
Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors.
Pancreas Volume: 48 Page(s): 510 - 513
04/01/2019 Authors: Samdani RT; Wasylishen AR; Halperin DM; Dasari A; Yao JC; Rashid A; Estrella JS
Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
BMC Cancer Volume: 19 Page(s): 274
03/28/2019 Authors: Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors.
Pancreas Volume: 48 Page(s): 381 - 386
03/01/2019 Authors: Halperin DM; Lee JJ; Ng CS; Strosberg JR; Estrella JS; Dagohoy CG; Dasari A; Yao JC
Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors.
Pancreas Volume: 48 Page(s): 1373 - 1379
01/01/2019 Authors: Shen C; Gu D; Zhou S; Xu Y; Sarshekeh AM; Halperin D; Shih Y-CT; Yao JC; Dasari A
Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.
BMC Med Res Methodol Volume: 18 Page(s): 169
12/12/2018 Authors: Serpas VJ; Raghav KP; Halperin DM; Yao J; Overman MJ
Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.
Sci Rep Volume: 8 Page(s): 16863
11/15/2018 Authors: Shen C; Dasari A; Xu Y; Zhou S; Gu D; Chu Y; Halperin DM; Shih YT; Yao JC
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.
Medicine (Baltimore) Volume: 97 Page(s): e13390
11/01/2018 Authors: Halperin DM; Huynh L; Beaumont JL; Cai B; Totev T; Bhak RH; Duh MS; Neary MP; Cella D
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors.
Pharmacoeconomics Volume: 36 Page(s): 1005 - 1013
08/01/2018 Authors: Shen C; Dasari A; Gu D; Chu Y; Zhou S; Xu Y; Halperin D; Fu S; Yao JC; Shih Y-CT
Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases.
Ann Surg Oncol Volume: 25 Page(s): 1709 - 1715
06/01/2018 Authors: Cloyd JM; Omichi K; Mizuno T; Kawaguchi Y; Tzeng C-WD; Conrad C; Chun YS; Aloia TA; Katz MHG; Lee JE
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
J Natl Compr Canc Netw Volume: 16 Page(s): 693 - 702
06/01/2018 Authors: Shah MH; Goldner WS; Halfdanarson TR; Bergsland E; Berlin JD; Halperin D; Chan J; Kulke MH; Benson AB; Blaszkowsky LS
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
Oncologist Volume: 22 Page(s): 1451 - 1462
12/01/2017 Authors: Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih Y-CT
Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis.
Oncotarget Volume: 8 Page(s): 99541 - 99551
11/21/2017 Authors: Mehrvarz Sarshekeh A; Advani S; Halperin DM; Conrad C; Shen C; Yao JC; Dasari A
Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Pancreas Volume: 46 Page(s): 1180 - 1187
10/01/2017 Authors: Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
JAMA Oncol Volume: 3 Page(s): 1335 - 1342
10/01/2017 Authors: Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors.
Ann Oncol Volume: 28 Page(s): 1582 - 1589
07/01/2017 Authors: Shen C; Dasari A; Chu Y; Halperin DM; Zhou S; Xu Y; Shih YT; Yao JC
Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
Clin Endocrinol (Oxf) Volume: 86 Page(s): 791 - 797
06/01/2017 Authors: Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC
Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply.
Lancet Oncol Volume: 18 Page(s): e300
06/01/2017 Authors: Halperin DM; Shen C; Yao JC
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Lancet Oncol Volume: 18 Page(s): 525 - 534
04/01/2017 Authors: Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih Y-CT; Yao JC
What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors.
J Clin Oncol Volume: 35 Page(s): 265 - 267
01/20/2017 Authors: Halperin DM; Yao JC; Dasari A
Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.
J Gastrointest Surg Volume: 21 Page(s): 155 - 163
01/01/2017 Authors: Prakash L; Bhosale P; Cloyd J; Kim M; Parker N; Yao J; Dasari A; Halperin D; Aloia T; Lee JE
Future Directions in the Biology of Neuroendocrine Tumors.
Pancreas Volume: 45 Page(s): 783 - 785
07/01/2016 Authors: Halperin DM; Dasari A; Yao JC
Update on management of midgut neuroendocrine tumors.
Int J Endocr Oncol Volume: 3 Page(s): 175 - 189
05/01/2016 Authors: Mehrvarz Sarshekeh A; Halperin DM; Dasari A
[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.
Future Oncol Volume: 12 Page(s): 313 - 321
02/01/2016 Authors: Halperin DM; Dasari A; Yao JC
Clinical Trial Design in Neuroendocrine Tumors.
Hematol Oncol Clin North Am Volume: 30 Page(s): 209 - 217
02/01/2016 Authors: Halperin DM; Yao JC
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.
J Clin Oncol Volume: 33 Page(s): 2914 - 2919
09/10/2015 Authors: Halperin DM; Lee JJ; Dagohoy CG; Yao JC
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Lancet Oncol Volume: 16 Page(s): 695 - 703
06/01/2015 Authors: Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Endocr Relat Cancer Volume: 22 Page(s): 431 - 441
06/01/2015 Authors: Dasari A; Phan A; Gupta S; Rashid A; Yeung S-CJ; Hess K; Chen H; Tarco E; Chen H; Wei C
A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Annu Rev Med Volume: 66 Page(s): 1 - 16
01/01/2015 Authors: Halperin DM; Kulke MH; Yao JC
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
BMC Cancer Volume: 14 Page(s): 561
08/02/2014 Authors: Halperin DM; Phan AT; Hoff AO; Aaron M; Yao JC; Hoff PM
Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?
Curr Oncol Rep Volume: 16 Page(s): 366
02/01/2014 Authors: Halperin DM; Varadhachary GR
Management of pancreatic neuroendocrine tumors.
Gastroenterol Clin North Am Volume: 41 Page(s): 119 - 131
03/01/2012 Authors: Halperin DM; Kulke MH
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation.
Proc Natl Acad Sci U S A Volume: 99 Page(s): 12351 - 12356
09/17/2002 Authors: Ulloa L; Ochani M; Yang H; Tanovic M; Halperin D; Yang R; Czura CJ; Fink MP; Tracey KJ

Directory section navigation

Profile